Imaging biomarkers for amyloid: a new generation of probes and what lies ahead

Int Psychogeriatr. 2014 May;26(5):703-7. doi: 10.1017/S1041610214000118. Epub 2014 Feb 13.

Authors

Antoine Leuzy¹, Eduardo Rigon Zimmer¹, Venkat Bhat², Pedro Rosa-Neto¹, Serge Gauthier³

Affiliations

¹ Translational Neuroimaging Laboratory (TNL), McGill Center for Studies in Aging (MCSA), Douglas Mental Health Research Institute, Montreal, Canada.
² Department of Psychiatry, McGill University, Montreal, Canada.
³ Alzheimer's Disease and Related Disorders Research Unit, McGill Center for Studies in Aging (MCSA), Douglas Mental Health Research Institute, Montreal, Canada Email: serge.gauthier@mcgill.ca.

PMID: 24524685
DOI: 10.1017/S1041610214000118

No abstract available

Publication types

Editorial

MeSH terms

Alzheimer Disease* / diagnosis
Alzheimer Disease* / metabolism
Amyloid* / analysis
Amyloid* / metabolism
Asymptomatic Diseases
Biomarkers / analysis
Biomarkers / metabolism
Diagnostic Imaging* / methods
Diagnostic Imaging* / trends
Diffusion of Innovation
Forecasting
Humans
Prognosis
Radiopharmaceuticals / pharmacology*

Substances

Amyloid
Biomarkers
Radiopharmaceuticals